Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Retension's $51.75M IPO buys a Phase 2b readout, but trial costs will set the clock

Retension's first earnings report since its upsized October IPO shows a $5.9M quarterly loss and a single catalyst: RTN-001 Phase 2b data in H1 2027. Peers show how thin other routes to capital are.

19 Nov 2026 · CompePharma editorial

What happened

On November 18, 2026, Retension Pharmaceuticals (Nasdaq: RTSN) reported third-quarter results and a corporate update. The quarter's net loss was $5.9 million. In October the company closed an upsized Nasdaq IPO with $51.75 million in gross proceeds.

The proceeds support a single program: RTN-001, a PDE5 inhibitor in a roughly 280-patient Phase 2b trial in uncontrolled hypertension. Topline data are expected in the first half of 2027. The company has linked its near-term story to that one readout.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →